Last reviewed · How we verify
DWC202405, DWC202314P
DWC202405 is a botulinum toxin type A inhibitor.
DWC202405 is a botulinum toxin type A inhibitor. Used for Upper limb spasticity in adults, Cervical dystonia in adults.
At a glance
| Generic name | DWC202405, DWC202314P |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | botulinum toxin type A inhibitor |
| Target | botulinum toxin type A |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation and reduction of muscle spasms.
Approved indications
- Upper limb spasticity in adults
- Cervical dystonia in adults
Common side effects
- Injection site pain
- Eyelid ptosis
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWC202405, DWC202314P CI brief — competitive landscape report
- DWC202405, DWC202314P updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI